TMS denied — the appeal blueprint for treatment-resistant depression

Why TMS gets denied

Transcranial magnetic stimulation (TMS) is FDA-cleared for major depressive disorder in adults who haven’t responded to one or more antidepressants in the current episode. Commercial plan medical policies typically apply a stricter standard, requiring documented inadequate response to at least two antidepressants from different classes. The denials almost always trace back to four patterns:

• Prior antidepressant trials not documented in enough detail. Names alone aren’t enough; the plan wants dates, doses, durations, and reasons for stopping.
• Drug-class diversity not met. Two SSRIs is one class. Two SNRIs is one class. Plans want two different classes — e.g., an SSRI and an SNRI, or an SSRI and an atypical (bupropion, mirtazapine).
• Trial duration or dose below threshold. “Therapeutic dose for an adequate trial” usually means 6–8 weeks at FDA-approved doses.
• Plan considers TMS investigational for the indication. Less common for adult MDD; more common for OCD, anxiety disorders, PTSD, and pediatric use.

What counts as a documented antidepressant trial

This is the single most important section of the appeal. Plan reviewers are looking for chart-level detail on each prior trial:

1. Medication name and class. SSRIs (sertraline, fluoxetine, escitalopram, citalopram, paroxetine), SNRIs (venlafaxine, duloxetine, desvenlafaxine), atypicals (bupropion, mirtazapine), tricyclics, MAOIs.
2. Start and stop dates. Specific months and years if exact days aren’t available.
3. Maximum dose reached. Within FDA-approved range. Sub-therapeutic doses don’t count.
4. Trial duration at therapeutic dose. Typically 6–8 weeks minimum.
5. Reason for stopping. Lack of efficacy, intolerable side effects (specify), non-adherence, switch by prescriber.
6. Outcome. PHQ-9 scores before and after if available; clinical impression of response.

Drug-class diversity — what plans actually mean

Two antidepressants from “different classes” generally means:

• SSRI: sertraline, fluoxetine, escitalopram, citalopram, paroxetine, fluvoxamine.
• SNRI: venlafaxine, duloxetine, desvenlafaxine, levomilnacipran.
• Atypical: bupropion, mirtazapine, vortioxetine, vilazodone, trazodone.
• Tricyclics: amitriptyline, nortriptyline, imipramine, desipramine.
• MAOIs: phenelzine, tranylcypromine, selegiline (transdermal).

For TMS coverage purposes, two failed SSRIs typically count as one class. Plans want diversity: an SSRI + an SNRI, an SSRI + an atypical, or any cross-class combination.

PHQ-9 scores and severity documentation

Most TMS medical policies expect documented depression severity at or near the time of the TMS request. The PHQ-9 is the standard tool:

• 0–4: Minimal depression
• 5–9: Mild depression
• 10–14: Moderate depression
• 15–19: Moderately severe depression
• 20–27: Severe depression

Many plan policies require a PHQ-9 score consistent with moderate-to-severe depression (typically 10 or higher, sometimes 15 or higher) at or near the TMS request. Include the most recent PHQ-9 and ideally a trajectory showing response (or lack of response) to prior treatment.

FDA labeling and APA practice guideline references

TMS for major depressive disorder is FDA-cleared. The first device (NeuroStar) was cleared in 2008; numerous devices and protocols have followed. The American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Major Depressive Disorder discusses TMS as a treatment option for patients who haven’t responded adequately to antidepressants.

For appeal purposes, cite:

• FDA clearance of TMS for major depressive disorder (or the specific cleared indication).
• The APA Practice Guideline reference for TMS in TRD.
• If applicable, additional society guidance (CANMAT, World Federation of Societies of Biological Psychiatry).

What makes a TMS appeal win vs. fail

Wins typically share these features:

1. Each prior antidepressant trial documented to chart-level detail (drug, class, dose, duration, outcome).
2. Drug-class diversity clearly satisfied — at minimum, two different classes.
3. Each trial at therapeutic dose for at least 6–8 weeks (or a documented intolerance preventing that).
4. Current PHQ-9 in moderate-to-severe range, with trajectory if available.
5. Treating psychiatrist’s letter explaining the clinical reasoning.
6. Plan medical-policy criteria mapped one-by-one to evidence in the chart.
7. FDA clearance and APA guideline citations.

Failures usually share these features: incomplete trial documentation, sub-therapeutic doses, duration cut short by side effects without proper documentation, two drugs from the same class, or missing severity measures.

What a strong TMS appeal letter contains

• Member ID, prior-auth number, requested CPT codes (typically 90867, 90868, 90869), treating psychiatrist, facility.
• The plan’s stated denial reason, quoted directly.
• A criterion-by-criterion mapping: plan requirement → corresponding chart evidence.
• The antidepressant trial table (drug, class, dose, dates, duration, outcome).
• Recent PHQ-9 score and trajectory.
• FDA-clearance and APA practice-guideline references.
• Treating psychiatrist’s clinical letter.
• Clear requested action: overturn the denial, authorize the requested TMS course.

If the internal appeal fails

You generally have the right to external review by an independent organization, with the decision binding on the insurer. See our internal vs external review guide for the full process. For TMS specifically, external reviewers (typically board-certified psychiatrists) frequently agree with the treating clinician when the documentation is strong, so the work that goes into the internal appeal often pays off twice.

Where InsureDefense helps

We map your TMS denial to the plan’s specific medical policy criteria, structure the antidepressant trial history at the chart-level detail plans want to see, and prepare an appeal letter that engages directly with FDA clearance and APA practice guidelines. See the TMS denial overview for a quick read on what your case will need, the parity-act guide for related behavioral-health appeal patterns, the medical necessity evidence guide, and the pillar appeal guide.

Start with a free triage See pricing